Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients
Authors:
- M. S. SampaioMSM. S. Sampaio
- Y. W. ChoYCY. W. Cho
- T. ShahTST. Shah
- S. BunnapradistSBS. Bunnapradist
- I. V. HutchinsonIHI. V. Hutchinson
- 24 January 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 27 (7) , 2971-2979
Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of transplantation. Using the OPTN/UNOS database, primary kidney recipients (2000-2009) were stratified according to transplant type (deceased donor, DD or living donor, LD), donor (D) and recipient (R) Epstein-Barr virus (EBV) serostatus (R+; D+/R- and D-/R-) and recipient age. Incidence and adjusted risk of PTLD and death were compared. Of the 137 939 primary kidney recipients transplanted between 2000 and 2009, 913 subsequently developed PTLD. In 90 208 recipients with known EBV serostatus, we found a trend toward a decrease in PTLD incidence in years 2007-2009 when compared to 2000-2003. This was due to a significant decrease in PTLD incidence in EBV- recipients. Of those, 61 273 had a known donor serostatus and were further examined. In adults, PTLD incidence (in 1000 person-years) in DD and LD was 7.0 and 7.0 in D+/R-; 3.0 and 2.5 in D-/R- and 1.2 and 1.0 in R+, respectively. The hazard ratio (HR) for PTLD (R+ as reference) in D+/R- (6.2 in DD and 7.2 in LD) was double to thrice than for D-/R- transplants (2.4 in both DD and LD). In pediatric recipients, PTLD incidence in DD and LD was 15.9 and 17.3 in D+/R-; 12 and 18 in D-/R- and 1.2 and 2.2 in R+, respectively. The HR for PTLD was 17.4 and 6.9 in D+/R- and 15.9 and 7.6 in D-/R- in DD and LD, respectively. A D+/R-, compared with a D-/R- transplant, may contribute to an increase in PTLD incidence of 35 and 42% in adult DD and LD transplants, respectively.Keywords
This publication has 22 references indexed in Scilit:
- Exosomes Containing Glycoprotein 350 Released by EBV-Transformed B Cells Selectively Target B Cells through CD21 and Block EBV Infection In VitroThe Journal of Immunology, 2011
- Using Epstein-Barr Viral Load Assays To Diagnose, Monitor, and Prevent Posttransplant Lymphoproliferative DisorderClinical Microbiology Reviews, 2010
- Epstein-Barr Virus and Posttransplant Lymphoproliferative Disorder in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2009
- Maribavir Inhibits Epstein-Barr Virus Transcription in Addition to Viral DNA ReplicationJournal of Virology, 2009
- Epstein-Barr Virus Vaccination of Transplant Candidates: Light at the End of the Tunnel?Transplantation, 2009
- Molecular and Immunologic Mechanisms of Cancer Pathogenesis in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2008
- Viral Infection after Renal TransplantationClinical Journal of the American Society of Nephrology, 2008
- Analysis of Factors that Influence Survival with Post-Transplant Lymphoproliferative Disorder in Renal Transplant Recipients: The Israel Penn International Transplant Tumor Registry ExperienceAmerican Journal of Transplantation, 2005
- Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipientsBritish Journal of Surgery, 2001
- Management of Epstein–Barr Virus-induced Post-transplant Lymphoproliferative Disease in Recipients of Solid Organ TransplantationAmerican Journal of Transplantation, 2001